Why Did TSHA Stock Surge Today: FDA Breakthrough Therapy Designation
-
最新报道：Taysha Gene Therapies (NASDAQ: TSHA) surged 47.28% to $4.6792 with over 80.7 million shares traded after the FDA granted Breakthrough Therapy designation to its gene therapy candidate TSHA-102 for Rett syndrome. The designation, based on a 100% response rate in Phase 1/2 trials, accelerates development and regulatory review for the treatment addressing approximately 10,000 US patients. Taysha confirmed alignment with the FDA on its pivotal trial protocol, with patient enrollment set for Q4 2025.
下一篇
Intuitive Machines (LUNR) Stock Gains on KinetX Acquisition
- Intuitive Machines (LUNR) shares surged 6.10% to $11.26 on October 2, 2025, following the ...
24小时热点
热点专题
417590